Rivaroxaban with aspirin
Brand:
NICE TA: 607
Indication: Prevention of cardiac events in patients with coronary (CAD) or peripheral artery Disease (PAD) (NICE TA607)
Disease category: Cardiovascular system
Commissioning responsibility: CCG
PbR excluded: No
Background
1.1 Rivaroxaban plus aspirin is recommended within its marketing authorisation, as an option for preventing atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease who are at high risk of ischaemic events.
Recommendation
LMMG recommendation: Green
Click here to find the definitions for the colour classifications
Reason for decision: Suitale for GP prescribing
Supporting documents:
Decisions of Lancashire local decision making groups:
NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
---|---|---|---|---|---|
Grey |